Structure Therapeutics Inc (GPCR)
33.41
+3.31
(+11.00%)
USD |
NASDAQ |
Nov 22, 16:00
33.44
+0.03
(+0.09%)
After-Hours: 20:00
Structure Therapeutics Cash from Financing (Quarterly): -0.757M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.757M |
| June 30, 2024 | 514.70M |
| March 31, 2024 | 0.702M |
| December 31, 2023 | 281.63M |
| September 30, 2023 | 0.473M |
| June 30, 2023 | -0.297M |
| Date | Value |
|---|---|
| March 31, 2023 | 169.73M |
| December 31, 2022 | -0.316M |
| September 30, 2022 | -0.259M |
| June 30, 2022 | 31.04M |
| March 31, 2022 | -1.448M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.448M
Minimum
Mar 2022
514.70M
Maximum
Jun 2024
90.47M
Average
0.473M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Viking Therapeutics Inc | 2.522M |
| Eli Lilly and Co | 211.30M |
| Novo Nordisk AS | -2.741B |
| Pfizer Inc | -4.636B |
| Amgen Inc | -3.651B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -19.70M |
| Cash from Investing (Quarterly) | -189.04M |
| Free Cash Flow | -104.33M |
| Free Cash Flow Per Share (Quarterly) | -0.3562 |
| Free Cash Flow Yield | -6.26% |